Atrial Fibrillation: Causes, Symptoms, Risk Factors, and Treatment

What Exactly Is Atrial Fibrillation?

Atrial fibrillation is a supraventricular arrhythmia in which disorganized electrical impulses fire from the pulmonary vein ostia and atrial myocardium at 350 to 600 beats per minute, replacing the normal P-wave with chaotic fibrillatory activity and producing an irregularly irregular ventricular response. The atria quiver rather than contract, stasis develops in the left atrial appendage, and thrombus formation follows, sharply raising embolic stroke risk. [1]

The condition is classified by duration. Paroxysmal AFib terminates spontaneously within seven days. Persistent AFib lasts longer than seven days or requires cardioversion. Long-standing persistent AFib continues beyond twelve months. Permanent AFib is present when both clinician and patient decide to stop pursuing sinus rhythm. Each category carries distinct management implications, though anticoagulation decisions depend on stroke risk score rather than AFib type alone. [2]

Worldwide, approximately 33.5 million individuals carry an AFib diagnosis, and age-standardized prevalence has risen steadily over the past three decades as populations age and cardiometabolic burden grows. [3] In the United States, the CDC estimates between 2.7 and 6.1 million Americans currently live with AFib, with projections reaching 12.1 million by 2030. [4]

How AFib Is Diagnosed

Diagnosis requires documentation of the arrhythmia on an ECG. The tracing shows absent P waves, an irregular R-R interval, and fibrillatory baseline activity. A standard 12-lead ECG suffices when AFib is ongoing during the visit. When symptoms are intermittent, a 24- to 48-hour Holter monitor, an extended two-to-four-week event monitor, or an implantable loop recorder may be needed. [5]

Once AFib is confirmed, a structured workup follows. Thyroid-stimulating hormone testing rules out thyrotoxicosis, a correctable cause. Echocardiography assesses left ventricular function, valvular disease, and left atrial size, all of which inform prognosis and treatment selection. Sleep-study referral is appropriate for patients with suspected obstructive sleep apnea because untreated apnea doubles AFib recurrence risk after ablation. [6]

A complete metabolic panel, lipid panel, and fasting glucose or HbA1c should be obtained at diagnosis. AFib rarely travels alone. In one analysis of Medicare beneficiaries with new-onset AFib, 57% carried concurrent hypertension, 31% had diabetes, and 26% had established coronary artery disease. [7]

Stroke Risk Assessment: The CHA2DS2-VASc Score

Every patient with AFib needs a formal stroke-risk score before anticoagulation is addressed. The CHA2DS2-VASc tool assigns one point each for congestive heart failure, hypertension, age 65-74, diabetes mellitus, vascular disease, and female sex, and two points each for age 75 or older and prior stroke or TIA. [8]

A score of zero in men or one in women (sex category only) indicates low risk, and anticoagulation may be withheld. A score of one in men or two in women warrants shared decision-making. Scores of two or higher in men and three or higher in women indicate clear net benefit from anticoagulation according to 2023 ACC/AHA atrial fibrillation guidelines. [9] The 2023 guidelines state: "In patients with AF and CHA2DS2-VASc score of 2 or greater in men and 3 or greater in women, anticoagulant therapy is recommended to reduce the risk of stroke and systemic thromboembolism (Class I, LOE A)."

Anticoagulation: DOACs vs. Warfarin

Direct oral anticoagulants (DOACs) have replaced warfarin as first-line therapy for nonvalvular AFib. Four DOACs carry FDA approval for this indication: apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). [10]

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with warfarin in patients with nonvalvular AFib. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs. 1.60% per year, P<0.001), cut major bleeding by 31%, and reduced all-cause mortality by 11%. [11] The RE-LY trial showed dabigatran 150 mg twice daily reduced stroke and systemic embolism by 34% compared with warfarin while maintaining similar major bleeding rates. [12]

Warfarin remains appropriate for patients with mechanical heart valves or moderate-to-severe mitral stenosis, where DOACs are contraindicated. For all other AFib patients, the 2023 ACC/AHA guidance supports DOAC use as the preferred strategy. Renal function must guide DOAC dosing. Apixaban dose-reduction criteria apply when two of three thresholds are met: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. [9]

Rate Control vs. Rhythm Control

Both strategies aim to reduce symptoms and prevent tachycardia-induced cardiomyopathy. Rate control slows the ventricular response without restoring sinus rhythm. Rhythm control uses cardioversion, antiarrhythmic drugs, or catheter ablation to restore and maintain normal sinus rhythm.

The RACE II trial (N=614) showed that a lenient rate-control target of below 110 bpm at rest was noninferior to a strict target of below 80 bpm for the composite of cardiovascular death, hospitalization for heart failure, stroke, systemic embolism, major bleeding, and life-threatening arrhythmia. [13] Beta-blockers and nondihydropyridine calcium channel blockers (diltiazem, verapamil) are first-line rate agents.

The landmark EAST-AFNET 4 trial (N=2,789) changed the rhythm-control calculus. Patients randomized to early rhythm control within one year of AFib diagnosis had a 21% lower rate of the primary composite outcome (cardiovascular death, stroke, worsening heart failure, or acute coronary syndrome) compared with usual care over five years (3.9 vs. 5.0 events per 100 person-years, P=0.005). [14] This trial established that early rhythm control, particularly in patients with cardiovascular comorbidities, reduces hard outcomes rather than merely improving symptoms.

Antiarrhythmic drugs used for rhythm control include flecainide and propafenone (in patients without structural heart disease), sotalol, dronedarone, and amiodarone. Amiodarone carries the highest efficacy but also the highest toxicity burden, including pulmonary, thyroid, hepatic, and corneal side effects, limiting its use to patients who fail other agents or have left ventricular dysfunction. [2]

Catheter Ablation: Who Benefits and What to Expect

Catheter ablation isolates the pulmonary veins electrically, targeting the primary trigger zones for AFib. In patients with symptomatic paroxysmal AFib who have failed at least one antiarrhythmic drug, ablation produces 65-75% freedom from AFib recurrence at 12 months, compared with roughly 50% for continued antiarrhythmic therapy. [15]

The CABANA trial (N=2,204) compared ablation with drug therapy as a first-line strategy. In the intention-to-treat analysis, ablation did not significantly reduce the primary composite endpoint, but a prespecified per-protocol analysis showed a 27% reduction in the composite of death, disabling stroke, serious bleeding, or cardiac arrest (P=0.006). [16] Ablation also produced substantially greater quality-of-life improvement and a 49% relative reduction in AFib recurrence.

For patients with AFib and heart failure with reduced ejection fraction (HFrEF), the CASTLE-AF trial (N=363) showed ablation reduced the composite of death and hospitalization for worsening heart failure by 38% compared with medical therapy (28.5% vs. 44.6%, P=0.006). [17]

Repeat ablation is sometimes needed. Roughly 20-30% of patients require a second procedure within three years, often for reconnection of previously isolated pulmonary veins. Procedural risks include cardiac tamponade (approximately 1%), pulmonary vein stenosis (<1%), and stroke (approximately 0.5%). [15]

Hypertension and AFib: A Two-Way Street

Hypertension is the single most prevalent modifiable risk factor for AFib, present in more than 70% of affected patients. Chronically elevated pressure causes left atrial pressure overload, atrial stretch, fibrosis, and electrical remodeling, all of which create the substrate for fibrillatory activity. [18]

Stage 1 hypertension (systolic 130-139 mmHg or diastolic 80-89 mmHg) and stage 2 hypertension (systolic 140 mmHg or higher or diastolic 90 mmHg or higher) both increase AFib risk, with risk scaling continuously with blood pressure level. A meta-analysis published in the European Heart Journal (N=1,249,316 participants) found that each 10 mmHg increment in systolic blood pressure was associated with a 6% higher AFib hazard. [19]

Renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors or angiotensin receptor blockers may attenuate atrial fibrosis beyond blood pressure lowering alone. Several trials support their use as "upstream therapy" to reduce new-onset AFib in hypertensive patients with left ventricular hypertrophy, though this indication is not yet FDA-approved. [18] Blood pressure targets should follow the 2017 ACC/AHA Hypertension Guideline threshold of below 130/80 mmHg for most adults with established cardiovascular disease or high risk. [20]

Metabolic Syndrome, Obesity, and AFib Risk

Metabolic syndrome, defined by the presence of three or more of the following (central obesity, elevated fasting glucose, elevated triglycerides, low HDL cholesterol, and elevated blood pressure), raises AFib incidence by approximately 49%. A 2020 meta-analysis pooling data from more than 1.18 million individuals found that metabolic syndrome carried a relative risk of 1.49 (95% CI 1.36-1.64) for incident AFib. [21]

Obesity drives a substantial share of this excess risk through multiple mechanisms. Increased epicardial fat volume promotes atrial inflammation and fibrosis. Elevated left ventricular filling pressures from obesity raise left atrial pressure. Obstructive sleep apnea, common in obese patients, causes nocturnal hypoxia and autonomic surges that trigger ectopic foci. [22]

Weight loss works. The LEGACY trial (N=355) demonstrated that obese AFib patients who achieved and maintained at least 10% body-weight loss had a 45% rate of long-term freedom from AFib at five years compared with 13% in those who lost less than 3% (P<0.001). [23] Clinically, this means that every kilogram lost in an obese AFib patient carries measurable rhythm benefit, independent of antiarrhythmic therapy.

GLP-1 receptor agonists present an emerging avenue. Semaglutide 2.4 mg weekly produced 14.9% mean weight loss over 68 weeks in the STEP-1 trial (N=1,961) and is increasingly used in patients with AFib and obesity. [24] Dedicated AFib outcomes data for semaglutide are not yet available from randomized trials, but cardiometabolic risk-factor reduction from significant weight loss may lower AFib burden indirectly.

Hyperlipidemia and Cardiovascular Risk in AFib Patients

AFib patients carry substantially elevated cardiovascular mortality risk beyond stroke. Coronary artery disease and heart failure frequently coexist, and hyperlipidemia drives both. The American College of Cardiology and American Heart Association recommend statin therapy for AFib patients who meet standard atherosclerotic cardiovascular disease (ASCVD) risk thresholds. [25]

High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) reduces LDL cholesterol by 50% or more and cuts major adverse cardiovascular events by approximately 25% per 1 mmol/L LDL reduction, as established across 26 randomized trials in a 2010 Lancet meta-analysis (N=169,138). [26] In AFib patients with established ASCVD or ten-year ASCVD risk of 7.5% or higher, statin therapy is a standard-of-care co-treatment alongside anticoagulation.

Several small trials have examined whether statins reduce AFib recurrence after cardioversion, but evidence remains inconsistent and statins are not currently indicated specifically for AFib rhythm control. The dominant rationale for statin use in AFib patients is reduction of myocardial infarction, coronary death, and atherosclerotic stroke, outcomes that anticoagulation alone does not address. [25]

AFib and Heart Failure With Preserved Ejection Fraction (HFpEF)

AFib and heart failure with preserved ejection fraction co-occur at high rates and worsen each other's prognosis. In a large registry analysis, approximately 65% of HFpEF patients had concurrent or antecedent AFib, compared with roughly 35% in patients with HFrEF. [27]

HFpEF is defined by an ejection fraction of 50% or higher combined with elevated natriuretic peptides and evidence of diastolic dysfunction or elevated filling pressures. The left atrial hypertension inherent to HFpEF creates a milieu for atrial remodeling, fibrosis, and AFib development. Conversely, AFib undermines diastolic filling by eliminating the atrial kick that contributes 20-30% of left ventricular preload, acutely worsening dyspnea. [28]

Management of concurrent AFib and HFpEF centers on four pillars. First, anticoagulation should follow the standard CHA2DS2-VASc framework, as HFpEF itself contributes one point. Second, aggressive treatment of hypertension to below 130/80 mmHg reduces left atrial pressure load. Third, diuresis with loop diuretics relieves congestion and may reduce AFib burden by lowering left atrial wall stress. Fourth, SGLT2 inhibitors (empagliflozin, dapagliflozin) have received FDA approval for HFpEF and reduce hospitalizations for worsening heart failure by approximately 21% (EMPEROR-Preserved trial, N=5,988); their impact on co-incident AFib burden is under active investigation. [29]

Lifestyle Modifications That Move the Needle

Pharmacology and ablation improve outcomes only when placed on a foundation of evidence-based lifestyle change. The ARREST-AF cohort (N=149) showed that patients who engaged in a structured risk-factor-management program (weight loss, blood pressure control, lipid management, diabetes treatment, alcohol reduction, and exercise) had a 46% lower rate of AFib recurrence than those who received standard care (P<0.001). [30]

Alcohol consumption deserves specific attention. Even moderate alcohol intake increases AFib risk. The HOLIDAY HEART syndrome describes acute AFib triggered by binge drinking, but chronic low-to-moderate intake also raises risk. A dose-response meta-analysis found that each additional drink per day increased AFib incidence by 8% (P<0.001). [31] Patients should be counseled to limit intake to no more than one drink per day or to abstain entirely.

Regular moderate-intensity aerobic exercise reduces AFib recurrence. The ACTIVE-AF trial (N=282) showed that patients randomized to a structured exercise program had a 40% lower AFib burden at 12 months compared with usual care (P=0.005). [32] Vigorous exercise performed chronically (defined as more than 1 to 500 hours of lifetime endurance sport) may paradoxically increase lone AFib risk in otherwise healthy athletes, an effect attributed to vagal remodeling and right atrial enlargement.

Sleep apnea treatment with CPAP reduces AFib recurrence after cardioversion. One prospective cohort study found that treated OSA patients had a 42% lower AFib recurrence rate at 12 months compared with untreated OSA patients (53% vs. 82% recurrence, P=0.013). [6]

When to Seek Urgent Evaluation

Rapid ventricular response in AFib, defined as heart rate consistently above 150 bpm, can cause hemodynamic compromise and requires urgent evaluation. Patients presenting with chest pain, dyspnea, hypotension, or syncope in the context of a rapid irregular pulse need immediate assessment, as acute AFib with rapid response may require emergency rate control with intravenous beta-blockers, diltiazem, or direct-current cardioversion if hemodynamically unstable. [2]

New neurological symptoms including facial drooping, arm weakness, speech difficulty, or sudden severe headache in any AFib patient represent a stroke emergency. Calling 911 immediately is the correct first step. Door-to-needle time for tPA administration is under 60 minutes at certified stroke centers, and every minute of delay translates to approximately 1.9 million neurons lost. [33]

Monitoring and Follow-Up Schedule

After diagnosis and treatment initiation, patients with AFib benefit from structured follow-up. The American Heart Association recommends reassessing rhythm status, anticoagulation adherence, DOAC renal dosing thresholds, and blood pressure control at every visit. Rate-control adequacy may be assessed with a resting ECG or 24-hour Holter. [9]

Renal function and electrolytes should be checked at least annually in patients on DOACs. Amiodarone requires thyroid function tests, liver enzymes, and pulmonary function assessment every six months. CHA2DS2-VASc score increases with age, so patients who initially scored below the treatment threshold should have their score recalculated yearly.